MedTrace Logo

Determining the Effect of Abiraterone on the Metabolism of Oxycodone in Men With Prostate Cancer (the ENABLE Study)

NCT07001709 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2025-06-03

No results posted yet for this study

Summary

Prostate cancer often leads to bone metastases, which require adequate pain management with opioids such as oxycodone. This study investigates whether abiraterone - a drug used in the treatment of prostate cancer - affects the pharmacokinetics of oxycodone in order to improve pain management.

Conditions

Interventions

DRUG

Oxycodone oral capsule 15 mg

Single dose of 15 mg oxycodone direct release (both arm 1 and arm 2)

DRUG

Abiraterone Acetate Tablets 500 mg

Abiraterone group: 1000 mg abiraterone acetate (at steady state)

Sponsors & Collaborators

  • Deventer Ziekenhuis

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-12
Primary Completion
2025-12-30
Completion
2026-01-30

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07001709 on ClinicalTrials.gov